Click here to get full coverage on HC Wainwright Issues Pessimistic Estimate for ALDX Earnings - MarketBeat

HC Wainwright Issues Pessimistic Estimate for ALDX Earnings  MarketBeat

HC Wainwright Issues Pessimistic Estimate for ALDX Earnings - MarketBeat

Click here to get full coverage on Why (ALDX) Price Action Is Critical for Tactical Trading - Stock Traders Daily

Why (ALDX) Price Action Is Critical for Tactical Trading  Stock Traders Daily

Why (ALDX) Price Action Is Critical for Tactical Trading - Stock Traders Daily

Click here to get full coverage on Is Aldeyra Therapeutics (ALDX) Outperforming Other Medical Stocks This Year? - Yahoo Finance

Is Aldeyra Therapeutics (ALDX) Outperforming Other Medical Stocks This Year?  Yahoo Finance

Is Aldeyra Therapeutics (ALDX) Outperforming Other Medical Stocks This Year? - Yahoo Finance

Click here to get full coverage on Aldeyra Therapeutics (NASDAQ: ALDX) outlines reproxalap, ADX-2191 and AbbVie deal - Stock Titan

Aldeyra Therapeutics (NASDAQ: ALDX) outlines reproxalap, ADX-2191 and AbbVie deal  Stock Titan

Aldeyra Therapeutics (NASDAQ: ALDX) outlines reproxalap, ADX-2191 and AbbVie deal - Stock Titan

Click here to get full coverage on ALDX: Net loss decreased to $33.8M in 2025; FDA decision on reproxalap and AbbVie option remain key catalysts - TradingView

ALDX: Net loss decreased to $33.8M in 2025; FDA decision on reproxalap and AbbVie option remain key catalysts  TradingView

ALDX: Net loss decreased to $33.8M in 2025; FDA decision on reproxalap and AbbVie option remain key catalysts - TradingView

Click here to get full coverage on Aldeyra Therapeutics (NASDAQ:ALDX) Shares Cross Below 200-Day Moving Average - Here's What Happened - MarketBeat

Aldeyra Therapeutics (NASDAQ:ALDX) Shares Cross Below 200-Day Moving Average - Here's What Happened  MarketBeat

Aldeyra Therapeutics (NASDAQ:ALDX) Shares Cross Below 200-Day Moving Average - Here's What Happened - MarketBeat

Click here to get full coverage on Does Aldeyra Therapeutics (ALDX) Have the Potential to Rally 79.28% as Wall Street Analysts Expect? - Zacks Investment Research

Does Aldeyra Therapeutics (ALDX) Have the Potential to Rally 79.28% as Wall Street Analysts Expect?  Zacks Investment Research

Does Aldeyra Therapeutics (ALDX) Have the Potential to Rally 79.28% as Wall Street Analysts Expect? - Zacks Investment Research

Click here to get full coverage on Does Aldeyra Therapeutics (NASDAQ:ALDX) Have A Healthy Balance Sheet? - simplywall.st

Does Aldeyra Therapeutics (NASDAQ:ALDX) Have A Healthy Balance Sheet?  simplywall.st

Does Aldeyra Therapeutics (NASDAQ:ALDX) Have A Healthy Balance Sheet? - simplywall.st

Click here to get full coverage on New Analyst Forecast: $ALDX Given $9.0 Price Target | ALDX Stock News - Quiver Quantitative

New Analyst Forecast: $ALDX Given $9.0 Price Target | ALDX Stock News  Quiver Quantitative

New Analyst Forecast: $ALDX Given $9.0 Price Target | ALDX Stock News - Quiver Quantitative

Click here to get full coverage on Aldeyra stock drops on FDA delay for lead drug (ALDX:NASDAQ) - Seeking Alpha

Aldeyra stock drops on FDA delay for lead drug (ALDX:NASDAQ)  Seeking Alpha

Aldeyra stock drops on FDA delay for lead drug (ALDX:NASDAQ) - Seeking Alpha

Click here to get full coverage on Noteworthy Wednesday Option Activity: GEV, ACMR, ALDX - Nasdaq

Noteworthy Wednesday Option Activity: GEV, ACMR, ALDX  Nasdaq

Noteworthy Wednesday Option Activity: GEV, ACMR, ALDX - Nasdaq

Click here to get full coverage on Is Aldeyra Therapeutics (ALDX) Surpassing Other Healthcare Stocks in Performance This Year? - Bitget

Is Aldeyra Therapeutics (ALDX) Surpassing Other Healthcare Stocks in Performance This Year?  Bitget

Is Aldeyra Therapeutics (ALDX) Surpassing Other Healthcare Stocks in Performance This Year? - Bitget

Click here to get full coverage on Biotech CEO in fireside chat at Oppenheimer health conference - Stock Titan

Biotech CEO in fireside chat at Oppenheimer health conference  Stock Titan

Biotech CEO in fireside chat at Oppenheimer health conference - Stock Titan

Click here to get full coverage on Understanding Momentum Shifts in (ALDX) - Stock Traders Daily

Understanding Momentum Shifts in (ALDX)  Stock Traders Daily

Understanding Momentum Shifts in (ALDX) - Stock Traders Daily

Click here to get full coverage on Aldeyra Therapeutics, Inc.'s (NASDAQ:ALDX) recent 10% pullback adds to one-year year losses, institutional owners may take drastic measures - Yahoo Finance

Aldeyra Therapeutics, Inc.'s (NASDAQ:ALDX) recent 10% pullback adds to one-year year losses, institutional owners may take drastic measures  Yahoo Finance

Aldeyra Therapeutics, Inc.'s (NASDAQ:ALDX) recent 10% pullback adds to one-year year losses, institutional owners may take drastic measures - Yahoo Finance

Click here to get full coverage on Aldeyra (NASDAQ: ALDX) reports FDA inspections of reproxalap facilities closed with VAI - Stock Titan

Aldeyra (NASDAQ: ALDX) reports FDA inspections of reproxalap facilities closed with VAI  Stock Titan

Aldeyra (NASDAQ: ALDX) reports FDA inspections of reproxalap facilities closed with VAI - Stock Titan

Click here to get full coverage on Avoiding Lag: Real-Time Signals in (ALDX) Movement - Stock Traders Daily

Avoiding Lag: Real-Time Signals in (ALDX) Movement  Stock Traders Daily

Avoiding Lag: Real-Time Signals in (ALDX) Movement - Stock Traders Daily

Click here to get full coverage on JonesTrading Lifts Aldeyra Therapeutics, Inc. (ALDX) Price Target to $9 - Yahoo Finance

JonesTrading Lifts Aldeyra Therapeutics, Inc. (ALDX) Price Target to $9  Yahoo Finance

JonesTrading Lifts Aldeyra Therapeutics, Inc. (ALDX) Price Target to $9 - Yahoo Finance

Click here to get full coverage on Aldeyra Therapeutics (ALDX) Upgraded to Strong Buy: What Does It Mean for the Stock? - Yahoo Finance

Aldeyra Therapeutics (ALDX) Upgraded to Strong Buy: What Does It Mean for the Stock?  Yahoo Finance

Aldeyra Therapeutics (ALDX) Upgraded to Strong Buy: What Does It Mean for the Stock? - Yahoo Finance

Click here to get full coverage on Aldeyra Therapeutics (NASDAQ:ALDX) Stock Passes Below 200-Day Moving Average - Here's What Happened - MarketBeat

Aldeyra Therapeutics (NASDAQ:ALDX) Stock Passes Below 200-Day Moving Average - Here's What Happened  MarketBeat

Aldeyra Therapeutics (NASDAQ:ALDX) Stock Passes Below 200-Day Moving Average - Here's What Happened - MarketBeat

Click here to get full coverage on Mid to low cap healthcare stocks with the strongest earnings momentum (ALDX:NASDAQ) - Seeking Alpha

Mid to low cap healthcare stocks with the strongest earnings momentum (ALDX:NASDAQ)  Seeking Alpha

Mid to low cap healthcare stocks with the strongest earnings momentum (ALDX:NASDAQ) - Seeking Alpha

Click here to get full coverage on Aldeyra Therapeutics (NASDAQ:ALDX) Stock Price Passes Above 50 Day Moving Average - Should You Sell? - MarketBeat

Aldeyra Therapeutics (NASDAQ:ALDX) Stock Price Passes Above 50 Day Moving Average - Should You Sell?  MarketBeat

Aldeyra Therapeutics (NASDAQ:ALDX) Stock Price Passes Above 50 Day Moving Average - Should You Sell? - MarketBeat

Click here to get full coverage on Aldeyra Therapeutics (ALDX) Faces FDA Review Delay for Reproxala - GuruFocus

Aldeyra Therapeutics (ALDX) Faces FDA Review Delay for Reproxala  GuruFocus

Aldeyra Therapeutics (ALDX) Faces FDA Review Delay for Reproxala - GuruFocus

Click here to get full coverage on Aldeyra (ALDX) Receives Extended FDA Action Date for Reproxalap NDA - GuruFocus

Aldeyra (ALDX) Receives Extended FDA Action Date for Reproxalap NDA  GuruFocus

Aldeyra (ALDX) Receives Extended FDA Action Date for Reproxalap NDA - GuruFocus

Click here to get full coverage on Following a 4.3% decline over last year, recent gains may please Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) institutional owners - simplywall.st

Following a 4.3% decline over last year, recent gains may please Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) institutional owners  simplywall.st

Following a 4.3% decline over last year, recent gains may please Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) institutional owners - simplywall.st

Click here to get full coverage on Aldeyra: 2 CRLs And A Precedent Gap Ahead Of Repro's PDUFA Merit Caution (Rating Downgrade) - Seeking Alpha

Aldeyra: 2 CRLs And A Precedent Gap Ahead Of Repro's PDUFA Merit Caution (Rating Downgrade)  Seeking Alpha

Aldeyra: 2 CRLs And A Precedent Gap Ahead Of Repro's PDUFA Merit Caution (Rating Downgrade) - Seeking Alpha

Click here to get full coverage on Discipline and Rules-Based Execution in ALDX Response - Stock Traders Daily

Discipline and Rules-Based Execution in ALDX Response  Stock Traders Daily

Discipline and Rules-Based Execution in ALDX Response - Stock Traders Daily

Click here to get full coverage on Aldeyra Therapeutics: Pivotal FDA Decision After Reproxalap's Chamber Data - Seeking Alpha

Aldeyra Therapeutics: Pivotal FDA Decision After Reproxalap's Chamber Data  Seeking Alpha

Aldeyra Therapeutics: Pivotal FDA Decision After Reproxalap's Chamber Data - Seeking Alpha

Click here to get full coverage on Aldeyra says dry eye therapy undergoes FDA review (ALDX:NASDAQ) - Seeking Alpha

Aldeyra says dry eye therapy undergoes FDA review (ALDX:NASDAQ)  Seeking Alpha

Aldeyra says dry eye therapy undergoes FDA review (ALDX:NASDAQ) - Seeking Alpha

Click here to get full coverage on (ALDX) Movement as an Input in Quant Signal Sets - Stock Traders Daily

(ALDX) Movement as an Input in Quant Signal Sets  Stock Traders Daily

(ALDX) Movement as an Input in Quant Signal Sets - Stock Traders Daily

Click here to get full coverage on Don't Ignore The Insider Selling In Aldeyra Therapeutics - simplywall.st

Don't Ignore The Insider Selling In Aldeyra Therapeutics  simplywall.st

Don't Ignore The Insider Selling In Aldeyra Therapeutics - simplywall.st

Click here to get full coverage on Why Is Aldeyra Therapeutics Stock Falling Tuesday? - Aldeyra Therapeutics (NASDAQ:ALDX) - Benzinga

Why Is Aldeyra Therapeutics Stock Falling Tuesday? - Aldeyra Therapeutics (NASDAQ:ALDX)  Benzinga

Why Is Aldeyra Therapeutics Stock Falling Tuesday? - Aldeyra Therapeutics (NASDAQ:ALDX) - Benzinga

Click here to get full coverage on Aldeyra Therapeutics (ALDX) Leads in Earnings Momentum - GuruFocus

Aldeyra Therapeutics (ALDX) Leads in Earnings Momentum  GuruFocus

Aldeyra Therapeutics (ALDX) Leads in Earnings Momentum - GuruFocus

Click here to get full coverage on Behavioral Patterns of ALDX and Institutional Flows - Stock Traders Daily

Behavioral Patterns of ALDX and Institutional Flows  Stock Traders Daily

Behavioral Patterns of ALDX and Institutional Flows - Stock Traders Daily

Click here to get full coverage on Aldeyra Therapeutics, Inc. - Common Stock (NQ: ALDX - The Chronicle-Journal

Aldeyra Therapeutics, Inc. - Common Stock (NQ: ALDX  The Chronicle-Journal

Aldeyra Therapeutics, Inc. - Common Stock (NQ: ALDX - The Chronicle-Journal

Click here to get full coverage on After Two Regulatory Setbacks For Reproxalap, Can Aldeyra's Persistence Pay Off? - RTTNews

After Two Regulatory Setbacks For Reproxalap, Can Aldeyra's Persistence Pay Off?  RTTNews

After Two Regulatory Setbacks For Reproxalap, Can Aldeyra's Persistence Pay Off? - RTTNews

Click here to get full coverage on Aldeyra Therapeutics, Inc. (ALDX) Faces Scrutiny After - GlobeNewswire

Aldeyra Therapeutics, Inc. (ALDX) Faces Scrutiny After  GlobeNewswire

Aldeyra Therapeutics, Inc. (ALDX) Faces Scrutiny After - GlobeNewswire

Click here to get full coverage on Aldeyra Therapeutics: Reproxalap’s March 2026 FDA Decision Is The Defining Catalyst - Seeking Alpha

Aldeyra Therapeutics: Reproxalap’s March 2026 FDA Decision Is The Defining Catalyst  Seeking Alpha

Aldeyra Therapeutics: Reproxalap’s March 2026 FDA Decision Is The Defining Catalyst - Seeking Alpha

Click here to get full coverage on High Growth Tech Stocks To Watch In US August 2025 - simplywall.st

High Growth Tech Stocks To Watch In US August 2025  simplywall.st

High Growth Tech Stocks To Watch In US August 2025 - simplywall.st

Click here to get full coverage on ATA Creativity Global Among 3 Promising Penny Stocks - simplywall.st

ATA Creativity Global Among 3 Promising Penny Stocks  simplywall.st

ATA Creativity Global Among 3 Promising Penny Stocks - simplywall.st

Click here to get full coverage on Aldeyra Therapeutics Faces FDA PDUFA Date Extension - TipRanks

Aldeyra Therapeutics Faces FDA PDUFA Date Extension  TipRanks

Aldeyra Therapeutics Faces FDA PDUFA Date Extension - TipRanks

Click here to get full coverage on High Growth Tech Stocks In The US Market With Promising Potential - simplywall.st

High Growth Tech Stocks In The US Market With Promising Potential  simplywall.st

High Growth Tech Stocks In The US Market With Promising Potential - simplywall.st

Click here to get full coverage on Aldeyra Therapeutics: A Mispriced Gem With Reproxalap's CRL Creating A Golden Buying Opportunity - Seeking Alpha

Aldeyra Therapeutics: A Mispriced Gem With Reproxalap's CRL Creating A Golden Buying Opportunity  Seeking Alpha

Aldeyra Therapeutics: A Mispriced Gem With Reproxalap's CRL Creating A Golden Buying Opportunity - Seeking Alpha

Click here to get full coverage on 4 Biotech Stocks Seeing Explosive Momentum Gains - Benzinga

4 Biotech Stocks Seeing Explosive Momentum Gains  Benzinga

4 Biotech Stocks Seeing Explosive Momentum Gains - Benzinga

Click here to get full coverage on 4 Biotechnology Stocks Lead Momentum Gains Amid Strong Technicals - Benzinga

4 Biotechnology Stocks Lead Momentum Gains Amid Strong Technicals  Benzinga

4 Biotechnology Stocks Lead Momentum Gains Amid Strong Technicals - Benzinga

Click here to get full coverage on After A CRL Setback, Aldeyra Therapeutics Is A Compelling Speculative Buy (NASDAQ:ALDX) - Seeking Alpha

After A CRL Setback, Aldeyra Therapeutics Is A Compelling Speculative Buy (NASDAQ:ALDX)  Seeking Alpha

After A CRL Setback, Aldeyra Therapeutics Is A Compelling Speculative Buy (NASDAQ:ALDX) - Seeking Alpha

Click here to get full coverage on ALDX BREAKING NEWS: Aldeyra Therapeutics, Inc. 75% Stock - GlobeNewswire

ALDX BREAKING NEWS: Aldeyra Therapeutics, Inc. 75% Stock  GlobeNewswire

ALDX BREAKING NEWS: Aldeyra Therapeutics, Inc. 75% Stock - GlobeNewswire

Click here to get full coverage on Jefferies Initiates Aldeyra Therapeutics(ALDX.US) With Buy Rating, Announces Target Price $7 - 富途牛牛

Jefferies Initiates Aldeyra Therapeutics(ALDX.US) With Buy Rating, Announces Target Price $7  富途牛牛

Jefferies Initiates Aldeyra Therapeutics(ALDX.US) With Buy Rating, Announces Target Price $7 - 富途牛牛

Click here to get full coverage on Aldeyra Therapeutics Stock Craters to All-Time Low on FDA Letter - Investopedia

Aldeyra Therapeutics Stock Craters to All-Time Low on FDA Letter  Investopedia

Aldeyra Therapeutics Stock Craters to All-Time Low on FDA Letter - Investopedia

Click here to get full coverage on ALDX ALERT: Aldeyra Therapeutics (NASDAQ:ALDX) Investors - GlobeNewswire

ALDX ALERT: Aldeyra Therapeutics (NASDAQ:ALDX) Investors  GlobeNewswire

ALDX ALERT: Aldeyra Therapeutics (NASDAQ:ALDX) Investors - GlobeNewswire

Click here to get full coverage on ALDX Investors Have Opportunity to Join Aldeyra Therapeutics, In - GuruFocus

ALDX Investors Have Opportunity to Join Aldeyra Therapeutics, In  GuruFocus

ALDX Investors Have Opportunity to Join Aldeyra Therapeutics, In - GuruFocus

Click here to get full coverage on ALDX Up as FDA Accepts Resubmitted NDA for Eye Drug Reproxalap - Yahoo Finance

ALDX Up as FDA Accepts Resubmitted NDA for Eye Drug Reproxalap  Yahoo Finance

ALDX Up as FDA Accepts Resubmitted NDA for Eye Drug Reproxalap - Yahoo Finance

Click here to get full coverage on Aldeyra Therapeutics Inc (NASDAQ:ALDX) A Bull Case Theory - Yahoo Finance

Aldeyra Therapeutics Inc (NASDAQ:ALDX) A Bull Case Theory  Yahoo Finance

Aldeyra Therapeutics Inc (NASDAQ:ALDX) A Bull Case Theory - Yahoo Finance

Click here to get full coverage on ALDX SECURITIES REPORT: Aldeyra Therapeutics, Inc. - GlobeNewswire

ALDX SECURITIES REPORT: Aldeyra Therapeutics, Inc.  GlobeNewswire

ALDX SECURITIES REPORT: Aldeyra Therapeutics, Inc. - GlobeNewswire

Click here to get full coverage on Increasing unusual option volume: XPO JANX BRR ABTC EDU MDB SIG COGT ALDX CMRE - StreetInsider

Increasing unusual option volume: XPO JANX BRR ABTC EDU MDB SIG COGT ALDX CMRE  StreetInsider

Increasing unusual option volume: XPO JANX BRR ABTC EDU MDB SIG COGT ALDX CMRE - StreetInsider

Click here to get full coverage on Aldeyra Therapeutics Announces Chief Development Officer Resignation - TipRanks

Aldeyra Therapeutics Announces Chief Development Officer Resignation  TipRanks

Aldeyra Therapeutics Announces Chief Development Officer Resignation - TipRanks

Click here to get full coverage on Buy Rating for Aldeyra Therapeutics: Confidence in Reproxalap’s Approval and Financial Upside - TipRanks

Buy Rating for Aldeyra Therapeutics: Confidence in Reproxalap’s Approval and Financial Upside  TipRanks

Buy Rating for Aldeyra Therapeutics: Confidence in Reproxalap’s Approval and Financial Upside - TipRanks

Click here to get full coverage on Pharma News: Does ALDX have strong fundamentals - Weekly Gains Summary & Daily Volume Surge Trade Alerts - baoquankhu1.vn

Pharma News: Does ALDX have strong fundamentals - Weekly Gains Summary & Daily Volume Surge Trade Alerts  baoquankhu1.vn

Pharma News: Does ALDX have strong fundamentals - Weekly Gains Summary & Daily Volume Surge Trade Alerts - baoquankhu1.vn

Click here to get full coverage on Aldeyra Stock Slumps After FDA Says Drug Candidate For Dry Eyes Treatment Failed To Show Efficacy – Retail Stays Optimistic - Stocktwits

Aldeyra Stock Slumps After FDA Says Drug Candidate For Dry Eyes Treatment Failed To Show Efficacy – Retail Stays Optimistic  Stocktwits

Aldeyra Stock Slumps After FDA Says Drug Candidate For Dry Eyes Treatment Failed To Show Efficacy – Retail Stays Optimistic - Stocktwits

Click here to get full coverage on Why B. Riley Financial Shares Are Trading Higher By Around 25%; Here Are 20 Stocks Moving Premarket - Benzinga

Why B. Riley Financial Shares Are Trading Higher By Around 25%; Here Are 20 Stocks Moving Premarket  Benzinga

Why B. Riley Financial Shares Are Trading Higher By Around 25%; Here Are 20 Stocks Moving Premarket - Benzinga

Click here to get full coverage on Aldeyra Therapeutics chief development officer to step down by March 2026 - Investing.com

Aldeyra Therapeutics chief development officer to step down by March 2026  Investing.com

Aldeyra Therapeutics chief development officer to step down by March 2026 - Investing.com

Click here to get full coverage on Aldeyra Therapeutics Faces Major Setback: What’s Next? - timothysykes.com

Aldeyra Therapeutics Faces Major Setback: What’s Next?  timothysykes.com

Aldeyra Therapeutics Faces Major Setback: What’s Next? - timothysykes.com

Click here to get full coverage on Bragar Eagel & Squire, P.C. Is Investigating TechTarget and Aldeyra and Encourages Investors to Contact the Firm - GlobeNewswire

Bragar Eagel & Squire, P.C. Is Investigating TechTarget and Aldeyra and Encourages Investors to Contact the Firm  GlobeNewswire

Bragar Eagel & Squire, P.C. Is Investigating TechTarget and Aldeyra and Encourages Investors to Contact the Firm - GlobeNewswire

Click here to get full coverage on ALDX - Aldeyra Therapeutics Inc Latest Stock News & Market Updates - Stock Titan

ALDX - Aldeyra Therapeutics Inc Latest Stock News & Market Updates  Stock Titan

ALDX - Aldeyra Therapeutics Inc Latest Stock News & Market Updates - Stock Titan

Click here to get full coverage on Aldeyra Therapeutics Is Severely Undervalued Before PDUFA - Seeking Alpha

Aldeyra Therapeutics Is Severely Undervalued Before PDUFA  Seeking Alpha

Aldeyra Therapeutics Is Severely Undervalued Before PDUFA - Seeking Alpha

Click here to get full coverage on Why I'm Selling Aldeyra Therapeutics (ALDX) - Seeking Alpha

Why I'm Selling Aldeyra Therapeutics (ALDX)  Seeking Alpha

Why I'm Selling Aldeyra Therapeutics (ALDX) - Seeking Alpha

Click here to get full coverage on Aldeyra Therapeutics Has Data To Trigger AbbVie Partnership (ALDX) - Seeking Alpha

Aldeyra Therapeutics Has Data To Trigger AbbVie Partnership (ALDX)  Seeking Alpha

ALDX

Price Chart

Key Statistics

Technicals

About ALDX

Latest News

HC Wainwright Issues Pessimistic Estimate for ALDX Earnings - MarketBeat

Why (ALDX) Price Action Is Critical for Tactical Trading - Stock Traders Daily

Is Aldeyra Therapeutics (ALDX) Outperforming Other Medical Stocks This Year? - Yahoo Finance

Advanced Charts

Top Gainers

Top Losers